{"disease":{"id":"adenocarcinoma-gej","name":"adenocarcinoma gej"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05365581","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":398,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT07455422","title":"A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":266,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT07182149","title":"A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Normunity AccelCo, Inc.","has_results":false},{"nct_id":"NCT07260461","title":"The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT04014075","title":"DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT06059495","title":"Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":59,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT06888037","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07334431","title":"Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06871527","title":"Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT04430738","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":true},{"nct_id":"NCT07359443","title":"Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06299163","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Numab Therapeutics AG","has_results":false},{"nct_id":"NCT05315830","title":"A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"The First Affiliated Hospital of Bengbu Medical University","has_results":false},{"nct_id":"NCT06048081","title":"Early Access Program for Zolbetuximab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}